Flecainide

Common Uses

Flecainide is primarily used to restore a normal heart rhythm and maintain a regular heartbeat in people with specific heart rhythm disorders. It is typically prescribed for the following conditions:

• Atrial Fibrillation and Flutter: It is used to prevent episodes of paroxysmal atrial fibrillation or flutter that cause disabling symptoms.
• Supraventricular Tachycardia: It helps prevent paroxysmal supraventricular tachycardias (PSVT), including conditions like Wolff-Parkinson-White syndrome and AV nodal reentrant tachycardia.
• Ventricular Arrhythmias: It is used to prevent life-threatening irregular heartbeats that start in the lower chambers of the heart, such as sustained ventricular tachycardia.

Clinical Context

This medication is generally reserved for patients with serious symptoms or life-threatening conditions. Because of the way it affects the heart, it is often started in a hospital setting where the heart rhythm can be closely monitored by medical professionals. It is most commonly used in patients who do not have structural heart disease, such as a history of a heart attack or heart failure, as it may not be appropriate for those individuals.

How Flecainide Works

Flecainide belongs to a class of medications known as antiarrhythmics. It is used to treat and prevent certain types of serious irregular heartbeats by regulating the electrical activity within the heart muscle.

The heart relies on internal electrical impulses to tell the heart muscle when to contract and pump blood. These signals travel through the heart via specialized pathways. Flecainide works through the following mechanisms:

• Sodium channel blockade: It works by blocking the flow of sodium into the heart cells. Sodium is essential for creating and conducting the electrical signals that trigger a heartbeat.
• Slowing conduction: By interfering with these sodium channels, the medication slows the speed at which electrical impulses travel through the heart tissue.
• Stabilizing heart rhythm: This slowing effect helps the heart maintain a regular rhythm and prevents abnormal or rapid electrical signals from causing an irregular heartbeat (arrhythmia).

By acting directly on the heart tissue to manage these nerve impulses, flecainide helps the heart beat in a more stable and predictable pattern.

Common Side Effects

Many people using flecainide experience mild side effects. These may include:

• Dizziness or lightheadedness
• Vision problems, such as blurred vision, difficulty focusing, or seeing spots
• Headache
• Nausea or stomach discomfort
• Constipation
• Feeling weak or excessively tired
• Shaking or tremors

Serious Side Effects

Some side effects can be severe. Seek medical attention immediately if you notice:

• A new or worsening irregular heartbeat (arrhythmia)
• Chest pain
• Shortness of breath
• Swelling of the hands, feet, ankles, or lower legs
• Fainting
• Pounding or rapid heartbeat
• Yellowing of the skin or the whites of the eyes

Boxed Warning: Risk of Death or Cardiac Arrest

Clinical research, specifically the Cardiac Arrhythmia Suppression Trial (CAST), demonstrated that flecainide increased the risk of death or non-fatal cardiac arrest in patients who had a heart attack within the previous two years and experienced certain non-life-threatening heart rhythm issues. Because of these risks, the use of flecainide is restricted to patients with specific, highly symptomatic, or life-threatening arrhythmias.

Proarrhythmic Effects

Flecainide can cause new heart rhythm disturbances or worsen existing ones. This is referred to as a proarrhythmic effect. These effects can range from an increase in the frequency of irregular heartbeats to the development of more severe, life-threatening arrhythmias. Monitoring in a hospital setting is often required when treatment is first started or when the dosage is significantly increased.

Heart Failure

Flecainide can decrease the strength of the heart's contractions. It may cause or worsen heart failure, particularly in patients who already have structural heart disease, a history of heart failure, or reduced heart function. Patients are typically monitored for symptoms such as shortness of breath, swelling, or sudden weight gain.

Contraindications

Flecainide is not recommended for individuals with certain medical conditions, including:

• Recent heart attack (myocardial infarction).
• Second- or third-degree heart block, unless a functional artificial pacemaker is in place.
• Right bundle branch block when associated with a left hemiblock, unless a pacemaker is present.
• Cardiogenic shock.
• Known hypersensitivity or allergy to flecainide.

Additional Precautions

Electrolyte Imbalance: Potassium levels in the blood must be within a normal range before starting flecainide. Both high potassium (hyperkalemia) and low potassium (hypokalemia) can interfere with the drug's effectiveness or increase the risk of toxic effects.

Liver and Kidney Function: Because the liver and kidneys are responsible for processing and removing flecainide from the body, patients with severe impairment in these organs may require lower doses and more frequent blood tests to monitor drug levels.

Pacemaker Function: Flecainide can increase endocardial pacing thresholds, meaning a pacemaker may need more energy to stimulate the heart. The function of pacemakers and defibrillators should be evaluated before and during treatment.

Pregnancy

There are no adequate and well-controlled studies of flecainide use in pregnant women. In animal studies, high doses of the medication were associated with birth defects and fetal harm. Because flecainide is known to cross the placenta, it should be used during pregnancy only if the potential benefit justifies the potential risk to the developing fetus. If you are pregnant or planning to become pregnant, discuss the risks and benefits of this medication with your healthcare provider.

Breastfeeding

Flecainide is excreted into human breast milk. Due to the potential for serious adverse reactions in a nursing infant, a decision should be made whether to discontinue breastfeeding or discontinue the medication. This decision should take into account the importance of the drug to the mother's health. Consult your doctor to determine the safest course of action for you and your baby.

Available Forms

Flecainide is available in the following form:

• Oral Tablet: This medication is taken by mouth.

FDA Approval and Indications

Flecainide is approved by the FDA for the prevention of certain types of irregular heartbeats, including paroxysmal supraventricular tachycardias (PSVT) and paroxysmal atrial fibrillation or flutter (PAF) in patients without structural heart disease. It is also indicated for the treatment of documented, life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia.

Boxed Warning

The FDA has issued a boxed warning for flecainide based on findings from the Cardiac Arrhythmia Suppression Trial (CAST). This trial demonstrated that in patients with a recent heart attack (occurring between six days and two years prior) who had non-life-threatening ventricular arrhythmias, flecainide was associated with an increased risk of death or non-fatal cardiac arrest compared to a placebo.

Safety and Regulatory Restrictions

Flecainide has proarrhythmic effects, meaning it has the potential to cause new or worsened heart rhythm disturbances. Because of these risks, the FDA recommends that flecainide use be restricted to patients with life-threatening arrhythmias or highly symptomatic supraventricular arrhythmias where the benefits outweigh the potential risks.

Regulatory guidelines generally advise against the use of flecainide in patients with structural heart disease, such as those with a history of congestive heart failure or a previous myocardial infarction, due to the heightened risk of proarrhythmia and mortality in these groups.

FDA-Approved Indications

The U.S. Food and Drug Administration (FDA) has approved flecainide for the following uses:

• Prevention of paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia and Wolff-Parkinson-White syndrome.
• Prevention of paroxysmal atrial fibrillation or flutter (PAF) in patients who do not have structural heart disease.
• Treatment of documented life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia.

FDA Boxed Warning

Flecainide carries a boxed warning, the FDA's most serious warning, regarding its use in certain populations. Clinical trials found that patients with a recent heart attack who took flecainide had a higher risk of death or non-fatal cardiac arrest compared to those taking a placebo. Because of these risks, the FDA restricts its use to patients with the specific heart rhythm disorders listed above and generally advises against its use in patients with structural heart disease or recent heart attacks.

Regulatory Status

Flecainide was first approved by the FDA in 1985. It is classified as a Class IC antiarrhythmic agent. Due to the potential for serious side effects, the FDA recommends that treatment, particularly for certain ventricular arrhythmias, be started in a hospital setting where the patient's heart rhythm can be continuously monitored.